Oncology News Central (ONC)Which Studies at ASCO 2024 May Change Practice?

Emerging research from the 2024 ASCO Annual Meeting highlights critical findings in lung and blood cancers, emphasizing the potential for practice-changing results and the growing role of artificial intelligence in oncology.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, presents pivotal studies that could influence clinical practice in the treatment of lung and blood cancers. Key phase 3 trials and innovative approaches, including the use of artificial intelligence to reengage marginalized patient populations, are expected to provide significant updates and insights.

Key Points:

• NSCLC Research:
  • The phase 3 LAURA trial (Abstract LBA4) assesses osimertinib post-chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC). Previous retrospective studies have shown significant improvement in progression-free survival (PFS) with consolidation osimertinib.
  • The PALOMA-3 trial (Abstract LBA8505) compares subcutaneous versus intravenous amivantamab plus lazertinib in refractory EGFR-mutated advanced NSCLC. Subcutaneous administration may reduce the high risk of infusion reactions associated with intravenous delivery.
  • The KRYSTAL-12 trial (Abstract LBA8509) examines adagrasib versus docetaxel in patients with previously treated advanced or metastatic NSCLC with KRASG12C mutations.
  • Dr. Salman R. Punekar from NYU Langone Health highlights two posters on novel CAR T-cell therapy in solid tumors (TPS2699) and preliminary antitumor activity of NT-112 in KRASG12D mutations (TPS2677).
• Blood Cancer Research:
  • Longer-term follow-up data from pivotal phase 3 trials TRANSFORM-1 and MANIFEST-2 will be presented, focusing on ruxolitinib combinations with navitoclax or pelabresib in myelofibrosis.
  • There is a discussion on the need to change clinical trial endpoints to assess durable responses and improvements in overall survival or PFS, beyond spleen size reduction.
  • Dr. Aaron Gerds from Cleveland Clinic will present updated safety and efficacy data from MANIFEST-2 (Abstract 6502).
• Artificial Intelligence in Oncology:
  • A study on AI to reengage inner-city patients who missed colonoscopy appointments (Abstract 100) addresses the critical issues of marginalized populations and the application of AI in medicine.
  • Dr. Gerds emphasizes the importance of leveraging technology to better serve patients and the potential impact of this AI study on patient engagement and treatment adherence.

“LAURA is going to be a randomized phase 3 trial that will hopefully show how much benefit there is to osimertinib. Those results could be big.”
– Salman R. Punekar, MD, Thoracic Oncologist at NYU Langone Health’s Perlmutter Cancer Center in New York City

More on ASCO